Colorectal Cancer

Oncology Solutions

The global burden of colorectal cancer (CRC) is expected to increase by 60 percent to more than 2.2 million new cases and 1.1 million deaths by 2030.1 Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. While the participation rates in screening are increasing, one quarter of the adults aged 50 to 75 years have never been screened.2 The five-year survival rate for colon cancer found at the local stage is 90 percent, highlighting the benefits of early detection.3

The Patient Journey

  • Colon VCAR

    Efficient reading workflow solution for colonic lesion detection.

  • SIGNA™ Architect AIR™ Edition

    Our premium 3.0T, 70 cm wide bore MRI system leverages intelligent technology to enable patient-friendly exams with exceptional image quality.

  • Discovery RT Gen 3

    A specialized radiation therapy CT, ideal for oncology centers. Meets all needs for precise radiation therapy planning

  • SIGNA™ PET/MR with QuantWorks – 60cm

    Introducing SIGNA™ PET/MR with QuantWorks. Built with pioneering TOF and integrated with a 3.0T MR, its impressive quantitative accuracy and high count rate combined with ...

The latest in Oncology


INSIGHTS
1. Global patterns and trends in colorectal cancer incidence and mortality. Melina Arnold1, Mónica S Sierra1, Mathieu Laversanne1, Isabelle oerjomataram1, Ahmedin Jemal2, Freddie Bray1. Arnold M, et al. Gut 2017;66:683–691. doi:10.1136/gutjnl-2015-310912 683
2. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/colorectal-cancer-screening2?ds=1&s=colorectal cancer
3. https://www.gastroconsa.com/colon-cancer-statistics/

JB02161UK